Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline
3. Inter-patient variations in drug therapy
4. Variations in phase I metabolism
5. Causes of inter-patient variations
6. Phase I drug-metabolizing enzymes
7. Genetics of human CYP enzymes
8. Genetic polymorphism of CYP enzymes
9. Clinically important human phase I CYP isozymes
10. CYP2C19 pharmacogenetics
11. Psychotropic drugs metabolized by CYP2D6
12. Human CYP2D gene cluster
13. CYP2D6 genetic variants
14. Debrisoquine and CYP2D6 genetic polymorphism
15. Nortriptyline: an excellent example
16. Fluoxetine N-demethylation by CYP2D6 isoforms
17. CYP2D6 polymorphism: inter-ethnic difference
18. Debrisoquine phenotype: inter-ethnic difference
19. CYP2D6 polymorphism and drug inactivation
20. CYP2D6 polymorphism and prodrug activation
21. Metabolism of codeine
22. Morphine production in CYP2D6 EMs and PMs
23. Pain tolerance in CYP2D6 EMs and PMs
24. Codeine intoxication associated with CYP2D6 UM
25. CYP2D6 is expressed in human brain
26. CYP genetic polymorphism: issues
27. CYP genetic polymorphism: opportunity
28. Phenotyping towards individualized drug therapy
29. Genotyping towards individualized drug therapy
30. CYP2D6 genotyping towards individualized therapy
31. Genotyping/phenotyping methods: comparison
32. Phenotyping vs. genotyping: pros and cons
33. Potency of CYP2D6 inhibitor
34. Drug-drug interactions altered CYP2D6 activity
35. CYP2D6 polymorphism: psychopharmacotherapy
36. References

Topics Covered

• Inter-patient variations caused by Phase I drug metabolizing enzymes
• Genetic polymorphism of CYP2D6 and impact on psychopharmacotherapy
• Metabolism, pharmacokinetics, pharmacodynamics and toxicity
• Pharmacogenetics and pharmacogenomics move towards individualized drug therapy

Links

Series:

• Psychopharmacogenetics

Categories:

• Genetics & Epigenetics
• Metabolism & Nutrition
• Pharmaceutical Sciences

Talk Citation

Publication History

• Published on October 1, 2007

Financial Disclosures

• Prof. Aiming Yu has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.